Clinical trials: Liver Diseases, Alcoholic
Nonalcoholic Fatty Liver Disease
Observational Study About Patients Diagnosed With NAFLD
Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome.
- Trial name
- NCT05625750
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Non-alcoholic Steatohepatitis (NASH)
FTIH of ECC4703 in Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC4703 in healthy volunteers and participants with treatment unnecessary LDL-C under 160 mg/dL
- Trial name
- NCT05552274
- Testing
- ECC4703
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Eccogene
NAFLD, Diet Habit
Exploring the Mechanism of Dietary Pattern Improving MAFLD
investigators plan to observe the changes of biochemical indicators, body composition, gut microbiota, metabolomics in patients at different periods through balanced diet and Low-carbohydrate diet, so as to determine the…
- Trial name
- NCT05960396
- Testing
- Diet intervention
- Volunteers
- 80 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cirrhosis of the Liver, Alcoholic Cirrhosis
Optimized Remission in Alcohol-related Liver Cirrhosis
The incidence of liver cirrhosis is increased fivefold for men and tripled for women in the last forty years. The clinical course of liver cirrhosis includes complications of ascites, hepatic encephalopathy, variceal bleeding…
- Trial name
- Pro-ALC (NCT06866496)
- Testing
- Motivational interviews, Standard of Care (SOC)
- Where
- Denmark
- Volunteers
- 350 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Nonalcoholic Steatohepatitis, NASH
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to evaluate the safety and tolerability of single ascending doses of ALN-HSD in healthy participants (Part A) and multiple doses of ALN-HSD in patients with NASH (Parts B and C).
- Trial name
- NCT04565717
- Testing
- ALN-HSD
- Where
- 13 sites in United States, Belgium and 3 more
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Non Alcoholic Fatty Liver Disease, Steatohepatitis
Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease
To explore whether there is a different response to omega-3 fatty acid rich diet with respect to the hepatic fat fraction % (HFF), triglyceride, and ALT levels between the rs738409 minor allele (GG) and the common allele…
- Conditions
- Non Alcoholic Fatty Liver Disease, Steatohepatitis, Hypertriglyceridemia, Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1
- Trial name
- NCT01556113
- Testing
- Omega diet
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
Non-alcoholic Fatty Liver Disease, NAFLD
Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease
There is a significant association between autonomic dysfunction and symptoms experienced by NAFLD patients mediated by increased systemic inflammation and insulin resistance, resulting in deteriorating quality of life of…
- Conditions
- Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver, Nonalcoholic, Nonalcoholic Fatty Liver Disease
- Trial name
- AD-NAFLD (NCT02132780)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Virginia Commonwealth University
Diabetes Type 2, NAFLD
Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients
Patients with type 2 diabetes and non-alcoholic fatty liver disease will be enrolled. According to a parallel design, the participants will be randomized to a Portfolio diet or a monounsaturated fatty acid (MUFA)-rich diet (used…
- Trial name
- MEDEA (NCT03380416)
- Testing
- Portfolio Diet, MUFA Diet
- Where
- Italy
- Volunteers
- 49 people
- Sponsor
- Federico II University
Dietary Intake, NAFLD
Dietary Determinants in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
Patients with NAFLD and matched controls will be asked about their demographic status, and their previous year dietary intakes using a validated FFQ.
- Trial name
- NCT02649049
- Testing
- there is no intervention
- Where
- Iran
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Nutrition and Food Technology Institute
Non-Alcoholic Fatty Liver Disease
Investigation of Synbiotic Treatment in NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a liver condition in which fat builds up in the liver not caused by alcohol. The liver is an organ that is not designed to build up fat.
- Trial name
- INSYTE (NCT01680640)
- Testing
- Synbiotic, Maltodextrin
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Nonalcoholic Steatohepatitis
Effects of Alanine in Patients With Nonalcoholic Steatohepatitis
Purpose of this study is to assess the therapeutic efficacy of L-alanine in improving biological and histological findings by administrating 6-18g/day L-alanine for one year.
- Trial name
- NCT00586885
- Testing
- L-alanine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Keith D Lindor, M.D.
NASH - Nonalcoholic Steatohepatitis, Cirrhosis
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14
To validate the ability of the Methacetin Breath Test (MBT) to detect clinically significant portal hypertension (CSPH)/severe portal hypertension (SPH) defined as hepatic venous pressure gradient (HVPG) ≥ 10 mmHg and HVPG ≥ 12…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Portal Hypertension
- Trial name
- NCT03439189
- Testing
- Methacetin Breath Test, Emricasan
- Where
- France
- Volunteers
- 343 people
- Sponsor
- Meridian Bioscience, Inc.
Sleep Apnea, Obstructive, Fatty Liver
Prevalence of Non-alcoholic Fatty Liver Disease Among Non-obese Obstructive Sleep Apnea by Using Transient Elastography
Obstructive sleep apnea (OSA) and non-alcoholic fatty liver disease (NAFLD) are both common diseases related to metabolic diseases with potential cardiovascular consequences and liver complications respectively.
- Trial name
- NCT05351515
- Where
- Hong Kong
- Volunteers
- 861 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Non-alcoholic Fatty Liver Disease
6-week Safety and PD Study in Adults With NAFLD
IN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSESSED IN ADULTS WITH…
- Trial name
- NCT03256526
- Testing
- PF-06835919 Low Dose, PF-06835919 High Dose
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pfizer
Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-Invasive Diagnostic Tests for MASLD in Pediatric Population
This study aims to test the utility of Velacur ultrasound as a non-invasive, rapid, point of care diagnostic tool for detecting the presence and amount of hepatic steatosis in children and adolescents aged 2 - 20 years.
- Trial name
- NCT06218589
- Testing
- Velacur, MRI, Blood sample collection for biomarkers
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Emory University
Nonalcoholic Steatohepatitis
Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)
The purpose of this study is to assess if digoxin is safe and efficacious in treating patients with non-alcoholic steatohepatitis (NASH) within the approved target range of 0.7 to 1 ng/ml.
- Trial name
- NCT04216693
- Testing
- Digoxin tablet
- Where
- China
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non-Alcoholic Fatty Liver Disease, Liver Diseases
"CAP" Fetge Gras. Lifestyle Modification Program in Catalonia.
The main purpose of this study is to investigate whether an online lifestyle modification program for people with Metabolic Associated Fatty Liver Disease (MAFLD) through a mobile application produces a significant reduction in…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Diseases, Lifestyle, Healthy
- Trial name
- NCT04988633
- Testing
- Intervention CFG App, Control Group
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Hospital Clinic of Barcelona
Diabetes Type 2, NAFLD
Follow-up of NAFLD Patients With MRI-PDFF
The liver is a key organ in metabolism and contributes to T2DM development and insulin resistance via unclear mechanisms that may involve liver fat accumulation, inflammatory signals, and immune cells are proposed to play an…
- Trial name
- NCT04910178
- Testing
- Empagliflozin 25 MG, Ursodeoxycholic acid, Pentoxifylline 400 MG
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Asmaa Abdelfattah Elsayed
Non-alcoholic Fatty Liver Disease, Sleep Apnea, Obstructive
Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease
Obstructive sleep apnea (OSA) and nonalcoholic fatty liver disease (NAFLD) are frequently encountered in patients with metabolic syndrome (MS). Several data suggest that OSA per se could be a risk factor of liver injury.
- Trial name
- NASHSAS (NCT03373643)
- Testing
- OSA screening
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Non Alcoholic Fatty Liver Disease
The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease
The purpose of this study is to examine whether CPAP therapy can reduce or eliminate hepatic fat accumulation in obese children and adolescents.
- Trial name
- NCT02134522
- Testing
- Continuous positive airway pressure (CPAP).
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.